Amyotropic Lateral Sclerosis (ALS) clinical trials at UC Irvine

9 in progress, 4 open to eligible people

Showing trials for

  • MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

    open to eligible people ages 18-80

    A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

    Orange, California and other locations

  • HEALEY ALS Platform Trial - Master Protocol

    open to eligible people ages 18 years and up

    The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

    Orange, California and other locations

  • Clinical Procedures to Support Research in ALS

    open to eligible people ages 18 years and up

    The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.

    Irvine, California and other locations

  • Intermuscular Coherence as a Biomarker for ALS

    open to eligible people ages 20-80

    The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of ALS patients longitudinally to determine if IMC-βγ changes with ALS disease progression and whether such changes correlate with functional and clinical scores, or survival.

    Irvine, California and other locations

  • Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02

    Sorry, not accepting new patients

    The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS). No formal clinical hypotheses are being evaluated with concurrent controls. Secondary objectives include assessment of the safety of CNM-Au8 treatment in pALS. Safety will be assessed through the frequency of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs) assessed as 'severe', discontinuations due to TEAEs, and laboratory abnormalities assessed as clinically significant during routine clinical monitoring (as applicable).

    Orange, California and other locations

  • ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

    Sorry, in progress, not accepting new patients

    ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be up to a 152-week active treatment extension (ATE) during which all subjects will receive ABBV-CLS-7262.

    Irvine, California and other locations

  • TPN-101 in Patients With C9ORF72 ALS/FTD

    Sorry, in progress, not accepting new patients

    This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).

    Orange, California and other locations

  • AMX0035 for Amyotrophic Lateral Sclerosis Treatment

    Sorry, in progress, not accepting new patients

    The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

    Orange, California and other locations

  • PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

    Sorry, in progress, not accepting new patients

    This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.

    Orange, California and other locations

Our lead scientists for Amyotropic Lateral Sclerosis (ALS) research studies include .

Last updated: